BAY 2395840
Alternative Names: BAY 2395840 cholinate; BAY-2395840Latest Information Update: 27 Apr 2023
At a glance
- Originator Bayer
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 19 Apr 2023 Discontinued - Phase-I for Neuropathic pain (In volunteers) in Japan (PO), prior to April 2023 (NCT05406219)
- 19 Apr 2023 Discontinued - Phase-II for Neuropathic pain in Czech Republic (PO), prior to April 2023 (NCT05406219)
- 19 Apr 2023 Discontinued - Phase-II for Neuropathic pain in Germany (PO), prior to April 2023 (NCT05406219)